Published on February 19, 2025, 02:01 AM UTC
Hims & Hers (HIMS) stock plunged 26% on Tuesday despite a better-than-expected Q4 report, as investors worry about potential revenue loss from discontinued compounded weight-loss drugs. CFO Yemi Okupe downplayed these concerns, highlighting the company's diversified revenue stream and strong outlook for 2024, but Wall Street remains cautious amid industry-wide changes in semaglutide availability.
Published on: February 25, 2025, 05:01 PM UTC
Amazon's MGM Studios has taken creative control of the iconic James Bond film franchise, bolstering its streaming strategy amidst fierce competition from Netflix and Disney.
Published on: February 20, 2025, 06:02 PM UTC
Singapore's Abaxx Exchange to Launch Gold Futures Amid Soaring Prices and Demand for Safe Havens
Published on: February 20, 2025, 07:00 AM UTC
Ukraine's vast ilmenite reserves could become a key part of a deal with the US, exchanging critical minerals for continued military aid. However, unknowns such as cost, licensing, and security guarantees could hinder the deal's viability, despite Ukraine's potential to reduce US reliance on Russia and China for these minerals.
Published on: February 16, 2025, 02:01 PM UTC
OpenAI rejects Elon Musk's $97.4 billion offer, calls it an attempt to "disrupt his competition." Musk, who sued OpenAI last year, leads a competing AI startup and recently purchased Twitter.
Published on: February 15, 2025, 02:00 AM UTC